

Date: February 15, 2024

The Listing Department BSE Limited Phiroze Jeejeebhoy Towers Dalal Street, Fort, Mumbai 400 001 The Listing Department National Stock Exchange of India Limited Exchange Plaza, Bandra Kurla Complex, Bandra (East), Mumbai - 400 051

BSE Scrip Code: 524372

NSE Symbol: ORCHPHARMA

Dear Sir,

Sub: Compliant Report

Ref: Application under Regulation 37 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("SEBI (LODR) Regulations") for the proposed Scheme of Amalgamation & Arrangement amongst Orchid Pharma Limited (Amalgamated Company") and Dhanuka Laboratories Limited ("Amalgamating Company") ("Scheme")

This is in reference to the subject application. Please note that no complaints relating to the Scheme have been received during the prescribed period under Para A(6) of Part I to the SEBI Master circular no. SEBI/HO/CFD/POD-2/P/CIR/2023/93 dated June 20, 2023. The "Compliant Report" is enclosed herewith.

Thanking You, Yours faithfully,

For Orchid Pharma Limited

Kapil Dayya

Company Secretary & Compliance Officer



Complaint Report Part A

| Sr. | Particulars | Number |
|-----|---|--------|
| No. | | |
| 1. | Number of complaints received directly | Nil |
| 2. | Number of complaints forwarded by Stock Exchanges/ SEBI | Nil |
| 3. | Total Number of complaints/comments received (1+2) | Nil |
| 4. | Number of complaints resolved | NA |
| 5. | Number of complaints pending | NA |

Part B

| Sr. | Name of complainant | Date of complaint | Status |
|-----|---------------------|-------------------|--------|
| No. | | _ | a . |
| 1. | NA | NA | NA |
| 2. | NA | NA | NA |
| 3. | NA | NA | NA |

Abbreviation: 'NA' stands for not applicable.





Date: March 22, 2024

The Listing Department National Stock Exchange of India Limited Exchange Plaza, Bandra Kurla Complex, Bandra (East), Mumbai - 400 051

NSE Symbol: ORCHPHARMA

Dear Sir,

Sub: Complaints Report

Ref: Application under Regulation 37 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("SEBI (LODR) Regulations") for the proposed Scheme of Amalgamation & Arrangement amongst Orchid Pharma Limited (Amalgamated Company") and Dhanuka Laboratories Limited ("Amalgamating Company") ("Scheme")

This is in reference to the subject application. Please note that no complaints relating to the Scheme have been received during the prescribed period under Para A(6) of Part I to the SEBI Master circular no. SEBI/HO/CFD/POD-2/P/CIR/2023/93 dated June 20, 2023. The "Complaint Report" is enclosed herewith.

You are requested to take the same on record.

Thanking You, Yours faithfully,

For Orchid Pharma Limited

Company Secretary & Compliance Officer



COMPLAINT REPORT

Period of Complaints Report: February 23, 2024 to March 15, 2024

Part A

| Sr. | Particulars | Number |
|-----|--|--------|
| No. | * | |
| 1. | Number of complaints received directly | Nil |
| 2. | Number of complaints forwarded by Stock Exchanges | Nil |
| 3. | Total Number of complaints/comments received (1+2) | Nil |
| 4. | Number of complaints resolved | NA |
| 5. | Number of complaints pending | NA |

Part B

| Sr. | Name of complainant | Date of complaint | Status |
|-----|---------------------|-------------------|---------------------|
| No. | | - | (Resolved/ Pending) |
| 1. | NA | NA | NA |
| 2. | NA | NA | NA |
| 3. | NA | NA | NA |

Abbreviation: 'NA' stands for not applicable.

Company Secretary & Compliance Officer

Date: March 22, 2024